Last edition
News about "Major Adverse Cardiovascular Events"
GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults
New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.
Major Adverse Cardiovascular Events | 19/02/2026 | By News Bureau | 123
FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.
Major Adverse Cardiovascular Events | 21/10/2025 | By Dineshwori | 277
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy